Trials / Unknown
UnknownNCT05108779
QLF32004 Injection for the Treatment of Patients With Advanced Malignant Tumors
Phase Ia Clinical Study of Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLF32004 for Injection Monotherapy in Patients With Advanced Malignant Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety, tolerability, and recommended dose (RP2D) of QLF32004 in patients with advanced malignancies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLF32004 | In the phase, five dose groups were proposed.The frequency of administration was once a week, and the treatment cycle was 3 weeks. |
Timeline
- Start date
- 2021-11-09
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
- First posted
- 2021-11-05
- Last updated
- 2023-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05108779. Inclusion in this directory is not an endorsement.